Johnson & Johnson subsidiary Janssen has announced its esketamine nasal spray reduced depressive...
Janssen’s esketamine reduces symptoms in suicidal depression
Johnson & Johnson subsidiary Janssen has announced its esketamine nasal spray reduced depressive symptoms in adult major depressive disorder patients with suicidal ideation with intent when combined with the standard of care.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.